These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12606067)

  • 1. Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism.
    Tillerson JL; Miller GW
    J Neurosci Methods; 2003 Mar; 123(2):189-200. PubMed ID: 12606067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Tillerson JL; Caudle WM; Reverón ME; Miller GW
    Exp Neurol; 2002 Nov; 178(1):80-90. PubMed ID: 12460610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aging of the dopaminergic system and motor behavior in mice intoxicated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Schumm S; Sebban C; Cohen-Salmon C; Callebert J; Launay JM; Golmard JL; Boussicault L; Petropoulos I; Hild A; Rousselet E; Prigent A; Friguet B; Mariani J; Hirsch EC
    J Neurochem; 2012 Sep; 122(5):1032-46. PubMed ID: 22708926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Richardson JR; Caudle WM; Guillot TS; Watson JL; Nakamaru-Ogiso E; Seo BB; Sherer TB; Greenamyre JT; Yagi T; Matsuno-Yagi A; Miller GW
    Toxicol Sci; 2007 Jan; 95(1):196-204. PubMed ID: 17038483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
    Leng A; Mura A; Hengerer B; Feldon J; Ferger B
    Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
    J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Executive function deficits and glutamatergic protein alterations in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
    Pflibsen L; Stang KA; Sconce MD; Wilson VB; Hood RL; Meshul CK; Mitchell SH
    J Neurosci Res; 2015 Dec; 93(12):1849-64. PubMed ID: 26332770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
    Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
    Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic and progressive Parkinson's disease MPTP model in adult and aged mice.
    Muñoz-Manchado AB; Villadiego J; Romo-Madero S; Suárez-Luna N; Bermejo-Navas A; Rodríguez-Gómez JA; Garrido-Gil P; Labandeira-García JL; Echevarría M; López-Barneo J; Toledo-Aral JJ
    J Neurochem; 2016 Jan; 136(2):373-87. PubMed ID: 26500044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Social odor recognition: a novel behavioral model for cognitive dysfunction in Parkinson's disease.
    Monaghan MM; Leddy L; Sung ML; Albinson K; Kubek K; Pangalos MN; Reinhart PH; Zaleska MM; Comery TA
    Neurodegener Dis; 2010; 7(1-3):153-9. PubMed ID: 20197696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
    Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
    J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Holmer HK; Keyghobadi M; Moore C; Meshul CK
    Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
    Sconce MD; Churchill MJ; Greene RE; Meshul CK
    Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral motor recovery in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned squirrel monkey (Saimiri sciureus): changes in striatal dopamine and expression of tyrosine hydroxylase and dopamine transporter proteins.
    Petzinger GM; Fisher B; Hogg E; Abernathy A; Arevalo P; Nixon K; Jakowec MW
    J Neurosci Res; 2006 Feb; 83(2):332-47. PubMed ID: 16385585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of membrane and vesicular monoamine transporters in the neurotoxic and hypothermic effects of 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH(2)-MPTP).
    Numis AL; Unger EL; Sheridan DL; Chisnell AC; Andrews AM
    Mol Pharmacol; 2004 Sep; 66(3):718-27. PubMed ID: 15322265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute Restraint Stress Augments 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Neurotoxicity via Increased Toxin Uptake into the Brain in C57BL/6 Mice.
    Mitsumoto Y; Mori A
    Neurosci Bull; 2018 Oct; 34(5):849-853. PubMed ID: 29987518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical exercise counteracts MPTP-induced changes in neural precursor cell proliferation in the hippocampus and restores spatial learning but not memory performance in the water maze.
    Klein C; Rasińska J; Empl L; Sparenberg M; Poshtiban A; Hain EG; Iggena D; Rivalan M; Winter Y; Steiner B
    Behav Brain Res; 2016 Jul; 307():227-38. PubMed ID: 27012392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.